Healthcare act affirmed; Synapse adds jobs in Ohio; Efficiencies drive GSK inhaler plant;

> In a surprise decision, the Supreme Court has upheld the affordable healthcare act. Story

> Devicemaker Synapse Biomedical is using a $5.1 million state tax break to add 60 jobs to its Oberlin, OH, plant. Story

> Six workers can now handle four assembly lines that turn out 220,000 inhalers a day because of efficiencies built into GlaxoSmithKline's ($GSK) respiratory-drug plant in Ware, England. Story

> Suzhou Pharma will open a quality assurance operation in Lyndhurst, NJ, in an effort to marry Western cGMP know-how with Asian production expertise. Story

And Finally... The FDA user fee law bans 28 chemicals sold at corner stores as hygiene products, incense or plant food that are often used in synthetic drugs known as "bath salts." Story

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.